Skip to main content
Clinical Trials/IRCT20150629022965N19
IRCT20150629022965N19
Completed
Phase 2

Evaluating the effects of oral N-acetyl cysteine as an adjuvant therapy for pain management and serum level of oxidative stress bio-markers in patients with painful diabetic neuropathy: a double-blind randomized clinical trial

Hamedan University of Medical Sciences0 sites140 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Diabetic polyneuropathy.
Sponsor
Hamedan University of Medical Sciences
Enrollment
140
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age: 30 to 70 years old
  • History of type 2 diabetes at least one year ago
  • Hemoglobin A1c less than or equal to 10
  • Diabetic neuropathy with NDS score greater than or equal to 6, VAS scores for pain at least 4 and NSS score greater than or equal to 5
  • glomerular filtration rate more than 30

Exclusion Criteria

  • Type 1 diabetes
  • Pregnancy or breastfeeding
  • Diabetic foot ulcer
  • Neuropathy for reasons other than diabetes
  • History of cerebrovascular disease and discopathy
  • Use other medications to relieve symptoms of neuropathy
  • Use of alcoholic drinks or opioids

Outcomes

Primary Outcomes

Not specified

Similar Trials